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Abstract
Hepcidin is an iron regulatory hormone, involved also in immune response in vertebrates. It contains the N-terminal Asp-Thr-His site able to bind Cu(II) ions. A significant discrepancy exist in the literature regarding Cu(II) affinity of this site in hepcidin. Our study focused on the model DTHFPI-NH2 hexapeptide reflecting the N-terminal motif of mature hepcidin Using potentiometry, UV-vis and CD spectroscopies we demonstrated that DTHFPI-NH2 is the strongest Cu(II) binding peptide discovered so far. A competition assay with human serum albumin (HSA) confirmed this high affinity and demonstrated that DTHFPI-NH2. withdraws all Cu(II) from HSA under equimolar concentrations. Based on these results we propose that hepcidin could exist as Cu(II) complex in blood, especially under inflammatory conditions, when its serum concentration is elevated.
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Hepcidin (also known as LEAP-1) is a systemic iron regulatory hormone in mammals including humans [1] It was first discovered in liver, but can be also produced by a wide range of tissues, e.g. heart, brain, lungs, skeletal muscles, stomach, pancreas, kidneys [2,3] and macrophage-rich tissues [4]. Hepcidin has a dual function in humans. Originally it was proposed to have an antimicrobial function, but its maximum reported blood concentration is much lower than the IC50 for its antimicrobial activity (1.5 μM vs. 14 μM, respectively) [2,5], Later it was proven that hepcidin is in fact involved in local immune response, although its activity was assigned, at least in part, to its other mode of action [6]. The global and the most important function of hepcidin is the regulation of iron metabolism. Hepcidin is secreted in response to high blood iron, and binds to the only known iron exporter protein, ferroportin. The resulting complex is internalized by iron storing cells (like macrophages) and degraded, resulting in withholding iron inside these cells [1] .
	Hepcidin is coded in the genome and synthesized as a 84 aa prepropeptide with a signal sequence for endoplasmic reticulum and the consensus site for prohormone convertases. This site is cleaved by furin [7,8], leaving a 25 aa long final form that is rapidly secreted into the bloodstream, where it is present in the serum (cell-free) fraction (Fig. 1).


Scheme 1. Amino acid sequence of Hepcidin-25. The pattern of disulfide bonds marked according to [9].

The cysteine content of mature hepcidin is unusually high, at eight out of 25 amino acids. These cysteines are interconnected in four disulfide bonds (Scheme 1), which makes hepcidin similar to other antimicrobial peptides – defensins [9,10]. Interestingly, none of these bonds is essential for the iron regulatory function. Likely they act as enhancers of peptide stability in the bloodstream [11]. The loosely structured N-terminus, on the other hand, is indispensable for ferroportin internalization [12]. A removal of the first three residues or just replacement of His-3 with a non-aromatic amino acid results in a dramatic loss of hepcidin activity [13].
	Metal binding properties of hepcidin were explored by several research groups [14–17]. Counterintuitively, this iron regulatory hormone does not interact with Fe(II) directly. Instead, it binds Fe(III) in a reducing environment, but this property does not seem to be physiologically relevant [15]. As mentioned above, the hepcidin N-terminal sequence contains a His residue in position 3, which creates an NTS motif (also named ATCUN), known from serum albumins, other biological peptides and many model oligopeptides, with a significant contribution of Professor Imre Sóvágó and his collaborators [18–32]. The conditional Cu(II) binding constants at pH 7.4 (CK7.4) for these motifs are in the range of 1011 to 1014.5 M-1. As there is an interplay between metals in human body, metals other than iron were also tested for interaction with hepcidin, especially copper, which is known to have impact on iron homeostasis [33]. However, previous studies yielded inconsistent results [14,16,17]. In the most recent of these papers Kulprachakarn et al. presented potentiometric studies of Cu(II) binding to DTH-NH2 and MALDI-ToF experiments on DTHFPIAIF-NH2 (N-terminal hepcidin nonapeptide with the Cys residue replaced with Ala) and the full length hepcidin. They obtained binding constants at pH 7.4 of 1012.9, .108.8, and 107.7 M-1, respectively. Taking into account that the same DTH site is present in all three peptides, the CK7.4 values for the latter two constants are difficult to accept without a very solid line of evidence.




DTHFPI-NH2 peptide was synthesized in our laboratory on a Prelude™ peptide synthesizer (Protein Technologies, Inc.), according to the solid phase Fmoc strategy [34]. Crude peptides were analyzed and purified by HPLC on an Empower system (Waters) equipped with ACE 5 C18-300 analytical and semi-preparative columns (5 mm particle size, 4.6×250 mm and 8×250 mm, respectively). The mobile phase consisted of (A) 0.1% trifluoroacetic acid (TFA) in water and (B) 0.1% TFA in 90% acetonitrile in water. The pure lyophilized peptides were characterized on a ESI-Q-ToF Premier mass spectrometer (Waters), exhibiting correct molecular masses.

2.2 Potentiometry
Potentiometric titrations of DTHFPI-NH2 were performed on a Titrando 907 automatic titrator, using Biotrode electrode (Metrohm), which was calibrated daily by nitric acid titrations [35]. 0.1 M NaOH (carbon dioxide free) was used as titrant. Sample volumes of 1.4–1.5 ml were used. The samples contained 1 – 1.6 mM peptides, dissolved in 4 mM HNO3/96 mM KNO3. The Cu(II) complex formation was studied for the 1:1 stoichiometry using a 5–10 % excess of peptide over Cu(II), added as CuCl2 for the consistency of experiments, as NO3- ions have an interfering absorption band in the near-UV range [36]. All experiments were performed under argon at 25 oC, in the pH range of 2.4 to 11.8. The collected data were analyzed using the SUPERQUAD and HYPERQUAD programs [35,37]. Two to three titrations were included simultaneously into calculations, separately for protonation and Cu(II) complexation.

2.3. UV-visible (UV-vis) and CD spectroscopies
For pH-dependence studies of Cu(II) binding, samples containing the peptide and Cu(II) ions were titrated with NaOH in the pH range of 2.5-10, by careful manual additions of very small amounts of the concentrated base solution. In these experiments the peptide concentration used was 1 mM, and the ligand-to-metal ratio 1:0.8, in order to avoid precipitation of residual Cu(OH)2 during titrations. The UV-vis spectra were recorded at 25°C on a Cary 50-Bio (Varian) UV-vis spectrophotometer over the spectral range of 200-800 nm, while the circular dichroism (CD) spectra were obtained with a J-815 spectropolarimeter (JASCO), over the range of 250–800 nm. The optical path for all experiments was 1 cm. 
The parameters of the d-d band of the CuHL2+ complex were calculated from the spectra below pH 4, where only the aqua ion and this complex are present, using the complex concentrations calculated from potentiometric stability constants.

2.4. Albumin competition experiments




	The DTHFPI-NH2 peptide that mimics the N-terminal sequence of mature hepcidin was chosen for its good solubility and to provide a moderate extension of C-terminal sequence, compared to the DTH-NH2 peptide studied previously [17]. UV-visible and CD spectroscopic titrations were performed in order to characterize the Cu(II) complex formation. Fig. 1 shows the pH dependence of Cu(II) complexation by the peptide monitored by UV-vis and CD. The quantitative information on these complexes were obtained from potentiometric titrations, The peptide protonation and Cu(II) stability constants are presented in Tables 1 and 2, respectively. Table 2 also contains the spectroscopic parameters of two detected complexes, CuHL2+ present around pH 3-5 and CuH-2L-, dominant above pH 4.


Fig. 1. UV-vis (A) and CD (B) spectra of Cu(II) complexes of DTHFPI-NH2 in the pH range from 2.5 to 8.0, obtained at 25 C for 0.8 mM Cu(II) and 1.0 mM peptide. Arrows mark the direction of spectral changes.

Table 1.





a β(HnLm+) = [HnLm+]/([L(m-n)+][H+]n); b Asp side chain carboxylate, c His imidazole, d Asp N-terminal amine

Table 2.
Spectroscopic parameters and stability constants of Cu(II) complexes of DTHFPI-NH2 obtained from potentiometry at I = 0.1 M (KNO3) and 25 C. Standard deviation on the last digits of log β values provided by HYPERQUAD [37], are given in parentheses. Band assignments are done on the basis of previous literature [21,40].
Species	log βa	average pKa	UV-Vismax (nm) /  (M-1cm-1)	CDext (nm) /  (M-1cm-1)
CuHL2+	13.82(6)		725 / 17b	n.d.
CuH-2L-	0.41(5)	4.47(5) (potentiometry)4.51(1) (spectroscopy)	527 / 89b	566b / -0.48486b / +0.38314c / +1.38274d / -3.05
a β(CuHnL(m+2)+) = [CuHnL(m+2)+]/([Cu2+][L(m-n)+][H+]n), 
b d-d transition
c N- to Cu(II) charge transfer transitions
d NH2 to Cu(II) and Nim to Cu(II) charge transfer transitions


Fig. 2. Species distribution for Cu(II) complexes of DTHFPI-NH2 calculated on the basis of potentiometric stability constants for 0.8 mM Cu(II) and 1.0 mM peptide, as in spectroscopic studies. Open and closed dots represent values of spectroscopic parameters specific for individual complexes (725 for CuHL2+ and 314 for CuH-2L-).
In Fig. 2 the species distribution of Cu(II) complexes is compared to the evolution of selected spectroscopic parameters, characteristic to respective complexes. The agreement between the methods is excellent. In particular, the apparent pKa of the CuH-2L- complex formation obtained from potentiometry, 4.47 ± 0.05 is within the statistical error of the same value obtained from the fitting of titration curves to the Hill equation, 4.51 ± 0.01 (see Supplementary Fig. S1).
The spectroscopic parameters, together with the protonation stoichiometries allow us to assign the coordination modes to the complexes. The CuHL2+ complex contains the Cu(II) ion coordinated to a single nitrogen donor, and the unknown number of oxygen donors from the peptide or the solvent, as judged from both the position of its d-d band and the protonation stoichiometry [40]. There are two possibilities for this complex to be formed, either at the N-terminus or at the imidazole ring. The former case would involve the formation of a six-membered chelate ring with the Asp side chain carboxylate. The relative ability of these two coordinating groups to attract the Cu(II) ion were studied systematically in the past, with the general conclusion that the imidazole nitrogen is a more attractive ligand in 1N complexes [41]. However, the stability of the 1N complex detected hereby is about one log unit higher from those studied previously, which contained the N-terminal Ala rather than Asp residue. This requires an additional source of stabilization of the 1N species, so the participation of the N-terminal Asp chelate in the 1N complex cannot be excluded. Therefore, we consider the CuHL2+ complex as a mixture of these two complex types.
The CuH-2L- complex is characterized with the four-nitrogen (4N) coordination mode characteristic for ATCUN/NTS complexes [21,39,40]. In these complexes the central metal ion sits in the center of an approximate square whose edges are occupied by four nitrogen atoms, provided by the N-terminal amine, two subsequent peptide nitrogens and the N-1 nitrogen of the His imidazole ring. Such complexes are called square-planar, as the central metal ion, Cu(II) in our case, and all four coordinated nitrogen atoms are practically coplanar, and the angles between the respective Cu(II)-N bonds are close to 90. This geometry is supported by the absorption band near 500 nm and a characteristic fingerprint-like split pattern of d-d bands in the CD spectra. It also conforms with the stoichiometry of the CuH-2L- complex, in which the Cu(II) ion replaced four protons from four nitrogen ligands (the Asp side chain proton gets dissociated below pH 3, which is lower than the 4N complex formation, starting around pH 4. The Hill coefficient value n = 2.6 confirms a direct transition from the 1N to the 4N complex with the simultaneous release of three protons from the peptide molecule.




Fig. 3. Cu(II) exchange between complexes of HSA (grey) and DTHFPI-NH2 (light gray); black lines represent the system evolution in time. A. Cu(DTHFPI-NH2) + HSA results in no Cu(II) transfer. Concentrations: HSA 0.63mM (containing 75% NTS), DTHFPI-NH2 0.47 mM, Cu(II) 0.42mM with final HSA NTS: DTHFPI-NH2 : Cu ratios of 1:1:0.9; B. Cu(HSA) + DTHFPI-NH2 results in full Cu(II) transfer (arrows mark direction of changes); C. Quantitative analysis of experiment B. yielded a pseudo-1st order kinetics. Dashed lines mark the values of spectral parameter for pure complexes.

	HSA is the key Cu(II) transport and delivery protein in human blood serum [44]. Therefore an assessment of a potential biological relevance of an extracellular Cu(II) chelator should include an HSA competition test. The results of appropriate experiments are presented in Fig. 3. In order to test the reversibility of Cu(II) reaction with HSA and DTHFPI-NH2, we tested two orders of addition of reagents. In the first one we preformed the Cu(HSA) complex and then added DTHFPI-NH2 (Fig. 3B) while in the second the preformed Cu(DTHFPI-NH2) complex was added to HSA (Fig. 3A). In the first case, a full transfer of Cu(II) from HSA to DTHFPI-NH2 was observed, while no transfer occurred from DTHFPI-NH2 to HSA in the reversed experiment. The rate of transfer, obtained from the pseudo-1st order kinetic fit of changes of CD bands was 8.1 ± 0.8 × 10-4 s-1, corresponding to t½ of ca. 14 min.

4. Discussion
	The consistent set of results presented above demonstrates that the affinity of DTHFPI-NH2 to Cu(II) is in fact unusually high. The CI value of 14.66 surpasses all values reported so far for NTS peptides composed of natural amino acids. The previous record belonged to the N-terminus of endostatin, HSHR- (CI = 14.5) [45]. We would like to note that HSHR and DTHF sequences have similar Cu(II) binding affinities despite a different amino acid sequence, whereas the affinities of DTHF and DAHK are significantly different despite sequence similarities. The sources of differences of Cu(II) affinities of NTS/ATCUN motifs have been proposed to result from differences of acidities of individual peptide nitrogens [46]. This concept explains properties of some, but not all peptides [22], At this stage of our research we can only speculate that these differences result in part from various patterns of hydrogen bonding, stabilizing the water structure in the 2nd sphere of the complex. This issue requires further studies.
The high affinity DTHFPI-NH2 for Cu(II) ions was confirmed by a swift and qualitative transfer of Cu(II) from HSA to this peptide. The observed rate of transfer, 0.0008 s-1, corresponds well to the estimated dissociation constant of the Cu(HSA) complex when one assumes the near-diffusion-limit association constant (108 – 109 M-1 s-1) [47], and the conditional binding constant for HSA of 1012 M-1 [39]. Therefore, a dissociative mechanism of Cu(II) transfer from HSA to the peptide can be proposed.
	The affinity of Cu(II) to the hepcidin N-terminus is 457 times higher than HSA. Together with the demonstrated ability of the hepcidin binding site to compete with HSA directly, this value, if confirmed for the whole hepcidin molecule, indicates that hepcidin should be at least partially saturated with Cu(II) in the bloodstream during inflammation, because hepcidin concentrations in blood can reach as high as 1.5 μM [5]. Test calculations of distribution of 3 μM Cu(II) between 470 μM and 1.5 μM hepcidin at pH 7.4 indicate that ca. 1 μM of Cu(II) was bound by hepcidin, compared to 2 μM of Cu(II) attached to HSA. This indicates a high, 67% occupancy of hepcidin by Cu(II) ions.
	Obviously, these predictions must be confirmed for the whole hepcidin molecule, as there might be a certain degree of error when extrapolating the properties of the N-terminal hexapeptide. According to our previous research [22,39], such extrapolations from small NTS models (tri- or tetrapeptides) can somewhat overestimate binding constants. The key example is HSA, which binds Cu(II) 30-40 times weaker than its tri- and tetrapeptide models, DAH an DAHK). However, five or six orders of magnitude of difference between the tripeptide DTH and full hepcidin, reported by Kulprachakarn et al. [17] cannot be explained by an idea of tertiary structure blocking the NTS. The metal-free N-terminus of hepcidin is unstructured, as determined by NMR spectroscopy [9], thus no significant steric hindrance can be held accountable for such a discrepancy, which must instead be attributed to the method used by them. Incidentally, the DTH tripeptide appears to bind Cu(II) nearly hundred times weaker than DTHFPI-NH2, stressing the role of secondary interactions in NTS/ATCUN complex stabilities.
	The problem with application of MALDI and other MS based methods to determination of affinity constants is that they work well only for sufficiently inert metal ions, such as Cu(I) or Zn(II) [48]. For a kinetically labile (although thermodynamically stable Cu(II) complexes, the effects are difficult to predict, especially when the entropic contribution to the complex stability is significant. In particular, the peptide and protein folding depends mostly on the entropy of the solvent. When there is not enough solvent present, entropy driven conformation is lost [49], and dehydration is the essence of MS experiment. Therefore, the MS-based affinity measurement for a Cu(II) complex requires a very strong confirmation, and the case of hepcidin warrants further studies in this respect.
The working conclusion from the above results is that hepcidin appears to have its NTS filled with Cu(II) in the bloodstream at least sometimes. This proposal prompts a speculation of its purpose. His-3 in hepcidin is conserved between fish, amphibians and mammals (excluding rodents) [50], but is not needed for iron regulatory activity itself. Substituting for a similarly large aromatic residue - Phe results in a hardly significant (8%) loss of hormone function, which does not explain the genetic conservation of this residue [13]. Hepcidin is upregulated in inflammation and could be induced locally even by macrophages/monocytes to reach high concentrations in proximity to inflammatory site [4]. High binding constant for copper may thus amplify hepcidin’s role in innate immune defense. One can speculate about hepcidin function in dually depleting microbes from available necessary metals. It was already proposed [51] that hepcidin could take part in starving microbes from iron. It is not entirely unreasonable to think that the same idea can apply to copper.

5. Conclusion
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